Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270175 · ClinicalTrials.gov registry record · Phase 2
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
A Phase 2 study of AL Amyloidosis and Amyloid, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT04270175 is a Phase 2 study of AL Amyloidosis and Amyloid that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 15 participants, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04270175, a Phase 2 study of AL Amyloidosis and Amyloid, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Daratumumab SC
Study Locations (4)
California
- Stanford University - Palo Alto
Massachusetts
- Boston University Medical Center - Boston
New York
- Weill Cornell Medicine - Multiple Myeloma Center - New York
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04270175
The ClinicalTrials.gov registry entry for NCT04270175 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with AL Amyloidosis appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT04270175 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04270175 about?
NCT04270175 is a clinical study titled "Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab". This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
What is the current status of trial NCT04270175?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-04-14. Estimated completion is 2028-01.
What conditions does trial NCT04270175 study?
This clinical trial studies the following conditions: AL Amyloidosis, Amyloid, Refractory AL Amyloidosis.
What interventions are being tested in trial NCT04270175?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Daratumumab SC (DRUG).
Who is sponsoring clinical trial NCT04270175?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04270175 being conducted?
This trial has 4 study locations across California, Massachusetts, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RECRUITING · Phase 2
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Ixazomib Maintenance Study in Patients With AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
COMPLETED · Phase 2
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.